en/health – 33. oldal

• Weight Loss in 2026: From Viral “Cutting Jelly” to GLP‑1 Meds—What’s Real, What’s Risky, and What to Do Instead
  2026-01-15

  Weight loss trends are colliding: viral “miracle” foods, powerful prescription injections and pills, and AI-generated health advice. Here’s how to separate evidence from hype and choose safer, sustainable steps.

• Weight-Loss Drugs in 2026: New Therapies, Safety Label Changes, and a Surge in Scams
  2026-01-15

  The weight-loss medication boom is expanding with new diabetes/obesity therapies, evolving FDA labeling discussions, and growing consumer risks from counterfeit and scam products. Here’s what to know and how to stay safe.

• Weight-Loss Medicines in 2026: Promising Diabetes Progress, Growing Competition, and a Rising Scam Threat
  2026-01-15

  New clinical updates suggest weight-loss medicines may deliver durable blood-sugar improvements and further weight reduction, while competition intensifies. At the same time, scams exploiting demand are surging—here’s how to protect your health and your wallet.

• Weight Loss in 2026: How Clinics, Medications, and Surgery Fit Together—and What Generic GLP‑1s Could Change
  2026-01-15

  A practical overview of modern weight-loss options—from structured clinic programs to GLP‑1 medications and bariatric surgery—plus what the arrival of generic weight-loss drugs may mean for access and safety.

• Weight-Loss Care in 2026: How to Choose Between Medication, Clinics, and Surgery (and What Generics May Change)
  2026-01-15

  Weight loss treatment is expanding beyond diet advice into structured programs, prescription medication, and bariatric surgery. Here’s how to decide where to start and what to expect as generic GLP‑1 drugs enter the market.

• Weight-Loss Medications in 2026: New Pills, Ongoing GLP-1 Debates, and What the FDA Said About Suicide Warnings
  2026-01-14

  A new weight-loss pill launch, renewed scrutiny of GLP-1 injections, and the FDA’s position on suicide warnings are shaping how people talk about obesity treatment in 2026. Here’s what the headlines mean in practical, health-focused terms.

• FDA Moves to Remove Suicide-Related Warnings From Some Weight-Loss Drug Labels: What It Means for Patients Using GLP-1s
  2026-01-14

  The FDA is asking manufacturers to remove suicide-related warnings from certain weight-loss drug labels, citing a review of available evidence. Here’s what changed, what didn’t, and how to approach GLP-1 treatment safely and sustainably.

• Weight-loss drugs, deepfake ads, and the latest FDA label change: what consumers should know
  2026-01-14

  GLP-1 weight-loss medications are evolving quickly—so are the risks, from misleading deepfake ads to confusion about drug-label warnings. Here’s what the FDA’s latest move may mean and how to protect yourself when seeking treatment.

• FDA to Drop Suicide Warnings for Some Weight-Loss Drugs: What It Means for Patients Using GLP-1 Medications
  2026-01-14

  The FDA says certain popular weight-loss drugs should no longer carry suicide-related warnings. Here’s what changed, what it doesn’t mean, and how to think about mental health while using GLP-1 medications.

• FDA moves to drop suicide warnings on GLP-1 weight-loss drugs as challenges and celebrity use keep demand high
  2026-01-14

  The FDA is moving to remove suicide-related warnings from certain GLP-1 weight-loss drugs, citing updated safety reviews. Here’s what the change does—and doesn’t—mean for people using these medications alongside diet, exercise, and structured programs.